Perioperative Chemo Improves Survival, Control in Esophageal Cancer
Patients with nonmetastatic esophageal cancer who received FLOT chemotherapy achieved a 3-year OS rate of 61.1% in an analysis of the phase 3 ESOPEC trial.
Related Articles
Safety Updates and Concluding Thoughts From Extended Follow-Up of MonumenTAL-1
Panelists discuss how talquetamab shows a more favorable safety profile with significantly lower high-grade infection rates compared with B-cell maturation antigen (BCMA)–directed bispecifics, although a…
Considerations for CAR T Use Across Large B-Cell Lymphoma Variants
Jose Sandoval Sus, MD, discussed the “revolution” that CAR T-cell therapies have facilitated for patients with large B-cell lymphomas.
Defining the Role of Immune Therapy in Multiple Myeloma
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.
Advances in ADC Therapy for Ovarian Cancer
Panelists discuss how the rapidly expanding ovarian cancer ADC pipeline offers promising therapeutic options with diverse payloads targeting folate receptor alpha and HER2, providing sequencing…
Tarlatamab Provides Clinicians New Immunologic Option in SCLC
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
Explicating Early-Line Treatment Considerations for EGFR-Mutant NSCLC
Following the approval of dato-DXd in untreated EGFR-mutant NSCLC, Jacob Sands, MD, discussed next steps for improving outcomes for this disease.
Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC
Zongertinib is now approved by the FDA for patients with non-squamous NSCLC with HER2 TKD activating mutations.
Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Creating a Seamless Transition from Pediatric to Adult Patient Cancer Care
While there is no clear and cut way to transition patients from pediatric to adult care, Maria C. Velez, MD, has established a helpful network…
NCCN Guidelines Add LEMS Antibody Testing for SCLC
Symptom specificity is now included in updated guidelines for SCLC relating to LEMS, characterized by proximal muscle weakness and autonomic dysfunction.